| Document and Entity Information (USD $) | 12 Months Ended | |
| Dec. 31, 2013 | Nov. 04, 2013 | |
| Document And Entity Information | ' | ' |
| Entity Registrant Name | 'Sunshine Biopharma, Inc | ' |
| Entity Central Index Key | '0001402328 | ' |
| Document Type | '10-K | ' |
| Document Period End Date | 31-Dec-13 | ' |
| Amendment Flag | 'false | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Is Entity a Well-known Seasoned Issuer? | 'No | ' |
| Is Entity a Voluntary Filer? | 'No | ' |
| Is Entity's Reporting Status Current? | 'Yes | ' |
| Entity Filer Category | 'Smaller Reporting Company | ' |
| Entity Public Float | ' | $5,242.11 |
| Entity Common Stock, Shares Outstanding | ' | 62,175,728 |
| Document Fiscal Period Focus | 'FY | ' |
| Document Fiscal Year Focus | '2013 | ' |
| Balance Sheet (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
| Current Assets: | ' | ' |
| Cash and cash equivalents | $31,240 | $132,638 |
| Prepaid expenses | 0 | 2,155 |
| Total Current Assets | 31,240 | 134,793 |
| TOTAL ASSETS | 31,240 | 134,793 |
| Current Liabilities: | ' | ' |
| Current portion of note payable | 12,500 | 62,500 |
| Accounts payable | 23,809 | 595 |
| Interest payable | 2,641 | 1,272 |
| TOTAL LIABILITIES | 38,950 | 64,367 |
| SHAREHOLDERS' EQUITY | ' | ' |
| Preferred stock, $0.10 par value per share; Authorized 5,000,000 Shares; Issued and outstanding -0- shares | 0 | 0 |
| Common Stock, $0.001 per share; Authorized 200,000,000 Shares; Issued and outstanding 60,299,061 and 51,416,092 at December 31, 2013 and December 31, 2012 respectively | 60,299 | 51,416 |
| Capital paid in excess of par value | 5,426,140 | 3,021,676 |
| Accumulated other comprehensive (Loss) | 0 | 0 |
| (Deficit) accumulated during the development stage | -5,494,149 | -3,002,666 |
| TOTAL SHAREHOLDERS' EQUITY | -7,710 | 70,426 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $31,240 | $134,793 |
| Balance Sheet (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
| SHAREHOLDERS' EQUITY | ' | ' |
| Preferred stock, par value | $0.10 | $0.10 |
| Preferred stock shares authorized | 5,000,000 | 5,000,000 |
| Preferred stock shares issued | 0 | 0 |
| Preferred stock shares outstanding | 0 | 0 |
| Common stock, par value | $0.00 | $0.00 |
| Common stock shares authorized | 200,000,000 | 200,000,000 |
| Common stock shares issued | 60,299,061 | 51,416,092 |
| Common stock shares outstanding | 60,299,061 | 51,416,092 |
| Unaudited Statement Of Operations (USD $) | 12 Months Ended | 49 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
| Income Statement [Abstract] | ' | ' | ' |
| Revenue: | $0 | $0 | $0 |
| General & Administrative Expenses | ' | ' | ' |
| Research and Development | 137,400 | 1,829 | 281,879 |
| Accounting | 23,640 | 18,190 | 73,275 |
| Consulting | 1,186,610 | 316,375 | 1,665,342 |
| Legal | 88,381 | 101,907 | 331,376 |
| Licenses | 475,000 | 250,000 | 1,175,000 |
| Office | 18,963 | 15,089 | 45,775 |
| Merger costs | 0 | 0 | 155,150 |
| Public Relations | 0 | 0 | 241,768 |
| Stock Transfer Fee | 6,083 | 3,290 | 21,930 |
| Writedown of intangible assets | 0 | 0 | 945,976 |
| Total G & A | 1,936,077 | 706,680 | 4,937,471 |
| (Loss) from operations | -1,936,077 | -706,680 | -4,937,471 |
| Other (expense): | ' | ' | ' |
| Interest expense | -6,455 | -1,272 | -7,727 |
| Beneficial conversion feature | -548,951 | 0 | -548,951 |
| Total Other (Expense) | -555,406 | -1,272 | -556,678 |
| Net (Loss) | ($2,491,483) | ($707,952) | ($5,494,149) |
| Basic (Loss) per common share | ($0.04) | ($0.01) | ' |
| Weighted Average Common Shares Oustanding | 55,395,819 | 49,775,134 | ' |
| Unaudited Statement Of Cash Flows (USD $) | 12 Months Ended | 49 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
| Cash Flows From Operating Activities: | ' | ' | ' |
| Net (Loss) | ($2,491,483) | ($707,952) | ($5,494,149) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
| Stock issued for licenses, services, and other assets | 1,246,310 | 272,875 | 2,673,702 |
| Stock issued for payment of expenses | 100,000 | 0 | 100,000 |
| Stock issued for payment interest on notes payable | 5,086 | 0 | 5,086 |
| Beneficial conversion feature on note conversion | 548,951 | 0 | 548,951 |
| (Increase) Decrease in prepaid expenses | 2,155 | 43,590 | 0 |
| Increase (decrease) in accounts payable | 23,214 | -2,839 | 23,809 |
| Increase in interest payable | 1,369 | 1,272 | 2,641 |
| Net Cash Flows (used) in operations | -564,398 | -393,054 | -2,139,960 |
| Cash Flows From Investing Activities: | ' | ' | ' |
| Net Cash Flows (used) in Investing activities | 0 | 0 | 0 |
| Cash Flows From Financing Activities: | ' | ' | ' |
| Proceed from note payable | 463,000 | 62,500 | 525,500 |
| Sale of common stock | 0 | 402,500 | 1,645,700 |
| Net Cash Flows provided by financing activities | 463,000 | 465,000 | 2,171,200 |
| Net Increase (Decrease) In Cash and cash equivalents | -101,398 | 71,946 | 31,240 |
| Cash and cash equivalents at beginning of period | 132,638 | 60,692 | 0 |
| Cash and cash equivalents at end of period | 31,240 | 132,638 | 31,240 |
| Supplementary Disclosure Of Cash Flow Information: | ' | ' | ' |
| Stock issued for services, licenses and other assets | 1,237,310 | 266,875 | 2,664,702 |
| Stock issued for payment of expenses | 100,000 | 0 | 100,000 |
| Stock issued for note conversions | 513,000 | 0 | 542,465 |
| Stock issued for net deficit of MWBS | 0 | 0 | -29,465 |
| Cash paid for interest | 0 | 0 | 0 |
| Cash paid for income taxes | $0 | $0 | $0 |
| Statement of Shareholders' Equity (USD $) | Common Stock | Capital Paid In Excess Of Par Value | Preferred Shares | Stock Subscription Receivable | Comprehensive Income | Deifict Accumulated During Development Stage | Total |
| Begining Balance, Amount at Aug. 16, 2009 | ' | ' | ' | ' | ' | ' | ' |
| Begining Balance, Shares at Aug. 16, 2009 | ' | ' | ' | ' | ' | ' | ' |
| August 20, 2009 issued 17,109,194 shares of par value $.001 common stock and 730,000 share of par value $0.10 preferred stock for license agreement Advanomics:Common valued at or $.004 per share and Preferred valued at or $.086 per share, Shares | 17,109,194 | ' | 850,000 | ' | ' | ' | ' |
| August 20, 2009 issued 17,109,194 shares of par value $.001 common stock and 730,000 share of par value $0.10 preferred stock for license agreement Advanomics:Common valued at or $.004 per share and Preferred valued at or $.086 per share, Amount | 17,109 | 55,891 | 73,000 | ' | ' | ' | 146,000 |
| September 24, 2009 : Private Placement-The Company undertook to sell 2,220,552 shares of par value $.001 common stock for cash of $649,000 or $.2922 per share. Company bought 1,150,693 share of par value $.001stock for cash of $336,312 or $.2922 per share; the remaining 1,069,859 shares were collected for cash of $312,688 in October 2009., Shares | 1,150,693 | ' | ' | ' | ' | ' | ' |
| September 24, 2009 : Private Placement-The Company undertook to sell 2,220,552 shares of par value $.001 common stock for cash of $649,000 or $.2922 per share. Company bought 1,150,693 share of par value $.001stock for cash of $336,312 or $.2922 per share; the remaining 1,069,859 shares were collected for cash of $312,688 in October 2009., Amount | 1,151 | 335,161 | ' | ' | ' | ' | 336,312 |
| September 30, 2009 issued 1,710,748 shares of par value $.001 common stock for asset purchase from Sunshine Bio Investment valued at or $.2922 per share, Shares | 1,710,748 | ' | ' | ' | ' | ' | ' |
| September 30, 2009 issued 1,710,748 shares of par value $.001 common stock for asset purchase from Sunshine Bio Investment valued at or $.2922 per share, Amount | 1,711 | 498,289 | ' | ' | ' | ' | 500,000 |
| Stock issued for services, Shares | 921,506 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, Amount | 921 | 3,011 | ' | ' | ' | ' | 3,932 |
| Net (Loss) | ' | ' | ' | ' | ' | -650,130 | -650,130 |
| Ending balance, Amount at Sep. 30, 2009 | 20,892 | 892,352 | 73,000 | -312,688 | 312,688 | -650,130 | 336,114 |
| Ending balance, Shares at Sep. 30, 2009 | 20,892,141 | ' | 850,000 | ' | ' | ' | ' |
| October 31, 2009 issuance of common stock subscription, upon receipt of cash 1,069,859 shs of par value $.001 common stock valued at $.2922 per share, Shares | 1,069,859 | ' | ' | ' | ' | ' | ' |
| October 31, 2009 issuance of common stock subscription, upon receipt of cash 1,069,859 shs of par value $.001 common stock valued at $.2922 per share, Amount | 1,070 | 311,618 | ' | 312,688 | -312,688 | ' | 312,688 |
| October 31, 2009 Outstanding stock of MWBS counted as issued for MWBS net deficit, Shares | 888,000 | -30,353 | ' | ' | ' | ' | ' |
| October 31, 2009 Outstanding stock of MWBS counted as issued for MWBS net deficit, Amount | 888 | ' | ' | ' | ' | ' | -29,465 |
| Subtotal-at October 31, 2009 reverse merger date for accounting purposes, Shares | 22,850,000 | ' | 850,000 | ' | ' | ' | ' |
| Subtotal-at October 31, 2009 reverse merger date for accounting purposes, Amount | 22,850 | 1,173,617 | 73,000 | ' | ' | -650,130 | 619,337 |
| November 16, 2009 Note conversions, several, Principle of $26,500 and interest of $2,965, Shares | 6,810,000 | 22,655 | ' | ' | ' | ' | ' |
| November 16, 2009 Note conversions, several, Principle of $26,500 and interest of $2,965, Amount | 6,810 | ' | ' | ' | ' | ' | 29,465 |
| Fractional Shares, Shares | 7 | ' | ' | ' | ' | ' | ' |
| Net (Loss) | ' | ' | ' | ' | ' | -551,000 | -551,000 |
| Ending balance, Amount at Dec. 31, 2009 | 29,660 | 1,196,272 | 73,000 | ' | ' | -1,201,130 | 97,802 |
| Ending balance, Shares at Dec. 31, 2009 | 29,660,007 | ' | 850,000 | ' | ' | ' | ' |
| Stock issued for services, Shares | 367,000 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, Amount | 367 | 236,833 | ' | ' | ' | ' | 237,200 |
| Stock issued for cash, Shares | 664,335 | ' | ' | ' | ' | ' | ' |
| Stock issued for cash, Amount | 664 | 397,936 | ' | ' | ' | ' | 398,600 |
| Net (Loss) | ' | ' | ' | ' | ' | -537,382 | -537,382 |
| Ending balance, Amount at Dec. 31, 2010 | 30,691 | 1,831,040 | 73,000 | ' | ' | -1,738,512 | 196,220 |
| Ending balance, Shares at Dec. 31, 2010 | 30,691,342 | ' | 850,000 | ' | ' | ' | ' |
| March 29, 2011 issued 20,000 shares of par value $.001 common stock for services valued at $ 12,000 or $.60 per share, Shares | 20,000 | 11,980 | ' | ' | ' | ' | ' |
| March 29, 2011 issued 20,000 shares of par value $.001 common stock for services valued at $ 12,000 or $.60 per share, Amount | 20 | ' | ' | ' | ' | ' | 12,000 |
| September 1, 2011 issued 326,00 shares of par value $.001 common stock in a private offering for cash at $0.60 per share, Shares | 326,000 | 195,274 | ' | ' | ' | ' | ' |
| September 1, 2011 issued 326,00 shares of par value $.001 common stock in a private offering for cash at $0.60 per share, Shares, Amount | 326 | ' | ' | ' | ' | ' | 195,600 |
| December 16, 2011 issued 291,500 shares of par value $.001 common stock for services for services valued at $ 55,385 or $.19 per share, Shares | 291,500 | 55,094 | ' | ' | ' | ' | ' |
| December 16, 2011 issued 291,500 shares of par value $.001 common stock for services for services valued at $ 55,385 or $.19 per share, Amount | 292 | ' | ' | ' | ' | ' | 55,385 |
| December 21, 2011 converted 850,000 shares of preferred stock into 17,000,000 shares of par value $.001 common stock, Shares | 17,000,000 | 56,000 | ' | ' | ' | ' | ' |
| December 21, 2011 converted 850,000 shares of preferred stock into 17,000,000 shares of par value $.001 common stock, Amount | 17,000 | -850,000 | -73,000 | ' | ' | ' | ' |
| Stock issued for services, Shares | 691,500 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, Amount | 692 | 254,694 | ' | ' | ' | ' | 255,385 |
| Net (Loss) | ' | ' | ' | ' | ' | -556,202 | -556,202 |
| Ending balance, Amount at Dec. 31, 2011 | 48,729 | ' | ' | ' | ' | -2,294,714 | 103,003 |
| Ending balance, Shares at Dec. 31, 2011 | 48,728,842 | 2,348,988 | ' | ' | ' | ' | ' |
| Common stock issued in private offering, Shares | 1,660,000 | ' | ' | ' | ' | ' | ' |
| Common stock issued in private offering, Amount | 1,660 | 400,839 | ' | ' | ' | ' | 402,500 |
| Stock issued for services, Shares | 1,027,250 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, Amount | 1,026 | 271,849 | ' | ' | ' | ' | 272,875 |
| Beneficial conversion feature | ' | ' | ' | ' | ' | ' | 0 |
| Net (Loss) | ' | ' | ' | ' | ' | -707,952 | -707,952 |
| Ending balance, Amount at Dec. 31, 2012 | 51,416 | ' | ' | ' | ' | -3,002,666 | 70,426 |
| Ending balance, Shares at Dec. 31, 2012 | 51,416,092 | 3,021,676 | ' | ' | ' | ' | ' |
| Stock issued for services, Shares | 5,292,543 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, Amount | 5,293 | 1,146,018 | ' | ' | ' | ' | 1,596,206 |
| Stock issued for debt and interest payable, Shares | 2,590,426 | ' | ' | ' | ' | ' | ' |
| Stock issued for debt and interest payable, Amount | 2,590 | 515,496 | ' | ' | ' | ' | 518,086 |
| Beneficial conversion feature | ' | 548,951 | ' | ' | ' | ' | 548,951 |
| Stock issued for cash, Shares | 1,000,000 | ' | ' | ' | ' | ' | ' |
| Stock issued for cash, Amount | 1,000 | 194,000 | ' | ' | ' | ' | 195,000 |
| Net (Loss) | ' | ' | ' | ' | ' | -2,491,483 | -2,491,483 |
| Ending balance, Amount at Dec. 31, 2013 | $60,299 | $5,426,140 | ' | $444,896 | ' | ($5,494,149) | ($7,710) |
| Ending balance, Shares at Dec. 31, 2013 | 60,299,061 | ' | ' | ' | ' | ' | ' |
| 1. Organization and Summary of Significant Accounting Policies | 12 Months Ended |
| Dec. 31, 2013 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
| Organization and Summary of Significant Accounting Policies | ' |
| ORGANIZATION | |
| Mountain West Business Solutions, Inc. (“MWBS”) was incorporated August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009 MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. The financial statements represent the activity of Sunshine Etopo, Inc. from August 17, 2009 (inception) through October 15, 2009, and the consolidated activity of Sunshine Etopo, Inc. and Sunshine Biopharma Inc. from October 15, 2009 forward. Sunshine Etopo, Inc. and Sunshine Biopharma, Inc. are hereinafter referred to collectively as the "Company". The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company. | |
| PRINCIPLES OF CONSOLIDATION | |
| The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. | |
| USE OF ESTIMATES | |
| The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
| STATEMENT OF CASH FLOWS | |
| For purposes of the statement of cash flows, the Company considered demand deposits and highly liquid-debt instruments purchased with maturity of three months or less to be cash equivalents. Cash paid for interest during the years ended December 31, 2013 and 2012 was $0. Cash paid for income taxes during the years ended December 31, 2013 and 2012 was $0. | |
| BASIC EARNINGS PER SHARE | |
| The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share. | |
| REVENUE RECOGNITION | |
| The Company is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company does not expect to generate revenues until clinical trials of its proposed products are completed. Once completed, revenues would be recognized as its technology is sold or its products become marketable. | |
| FINANCIAL INSTRUMENTS | |
| The carrying value of the Company’s financial instruments as reported in the accompanying balance sheet approximates fair value. | |
| STOCK BASED COMPENSATION | |
| The Company accounts for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable. | |
| DATE OF MANAGEMENT’S REVIEW | |
| Subsequent events have been evaluated through the date of the issuance of these financial statements. | |
| OFFICER COMPENSATION | |
| Through the period ended December 31, 2013 the officers and directors of the Company have not received any cash, stock, or other forms of compensation. | |
| LEGAL FEES | |
| During the years ended December 31, 2013 and 2012 legal fees were incurred as a result of services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission. |
| 2. Basis of Presentation | 12 Months Ended |
| Dec. 31, 2013 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
| 2. Basis of Presentation | ' |
| In the course of its life the Company has had limited operations, and has a working capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
| 3. Capital Stock | 12 Months Ended |
| Dec. 31, 2013 | |
| Notes to Financial Statements | ' |
| 3. Capital Stock | ' |
| The Company’s authorized capital is comprised of 200,000,000 shares of $0.001 par value Common Stock and 5,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company has designated 850,000 shares as Series A Preferred Stock (“Series A”). The Series A is convertible at any time after issuance into 20 shares of the Company's Common Stock with no further consideration, has full voting rights at 20 votes per share, and has superior liquidation rights to the common stock. Through December 31, 2013 and December 31, 2012, the Company has issued and outstanding a total of 60,299,061 and 51,416,092 shares of Common Stock and 0 and 0 shares of Series A Preferred Stock, respectively. | |
| On August 17, 2009, the Company issued 703,118 shares of $0.001 par value Common Stock for services valued at $3,000 or $0.004 per share. | |
| On August 19, 2009, the Company issued 218,388 shares of $0.001 par value Common Stock for services valued at $932 or $0.004 per share. | |
| On August 20, 2009, the Company issued 17,109,194 shares of $0.001 par value Common Stock for licenses valued at $73,000 or $0.004 per share. | |
| On August 20, 2009, the Company issued 850,000 shares of $0.10 par value of Series “A” Convertible Preferred Stock for licenses valued at $73,000, or $0.086 per share. | |
| In September and October, 2009, the Company issued 2,220,552 shares of $0.001 par value Common Stock for cash of $649,000 or $0.2922 per share as part of a private offering. | |
| On September 30, 2009, the Company issued 1,710,748 shares of $0.001 par value Common Stock for assets valued at $500,000 or $0.2922 per share. | |
| On October 31, 2009, the outstanding stock of Mountain West Business Solutions was counted as issued 888,000 shares of $0.001 par value Common Stock for Mountain West Business Solutions deficit of $ 29,465. | |
| On November 16, 2009, the Company note holders converted their notes to 6,810,000 shares of $0.001 par value Common Stock for principal of $26,500 and interest of $2,965. | |
| On June 2, 2010, the Company issued 1,675,000 shares of $0.001 par value Common Stock for services valued at $1,574,500 or $0.94 per share. | |
| On September 30, 2010, the Company reversed issuance of 1,625,000 shares of $0.001 par value Common Stock for services valued at $1,527,500 or $0.94 per share. | |
| On September 30, 2010, the Company issued 166,667 shares of $0.001 par value Common Stock for cash at $100,000 or $0.60 per share. | |
| On October 1, 2010, the Company issued 217,000 shares of $0.001 par value Common Stock for services valued at $130,000 or $0.60 per share. | |
| On October 29, 2010, the Company issued 100,000 shares of $0.001 par value Common Stock for services valued at $60,000 or $0.60 per share. | |
| On October 31, 2010, the Company issued 419,334 shares of $0.001 par value Common Stock for cash at $251,600 or $0.60 per share. | |
| On November 30, 2010, the Company issued 78,334 shares of $0.001 par value Common Stock for cash at $47,000 or $0.60 per share. | |
| On March 29, 2011, the Company issued 20,000 shares of $0.001 par value Common Stock for services valued at $12,000 or $0.60 per share. | |
| On September 1, 2011, the Company issued 326,000 shares of $0.001 par value Common Stock for cash at $195,600 or $0.60 per share. | |
| On November 3, 2011, the Company issued 400,000 shares of $0.001 par value Common Stock for services valued at $200,000 or $0.50 per share. | |
| On September 16, 2011, the Company issued 291,500 shares of $0.001 par value Common Stock for services valued at $55,385 or $0.19 per share. | |
| On December 21, 2011, the Company issued 17,000,000 shares of $0.001 par value Common Stock in exchange for the 850,000 shares of outstanding Series A Convertible Preferred Stock. At December 31, 2011 there is no Preferred Stock outstanding. | |
| In June of 2012 the Company issued 230,000 shares of $0.001 par value restricted common stock for services valued at $69,000 or $0.30 per share. | |
| In July 2012 the Company issued 44,000 shares of $0.001 par value restricted common stock for services valued at $15,400 or $0.35 per share. | |
| In August 2012 the Company issued 128,250 shares of $0.001 par value restricted common stock for services valued at $38,475 or $0.30 per share. | |
| In August 2012 the Company issued 600,000 shares of $0.001 par value restricted common stock for services valued at $144,000 or $0.24 per share. | |
| In October 2012 the Company issued 25,000 shares of $0.001 par value restricted common stock for services valued at $6,000 or $0.24 per share. | |
| In January 2013 the Company issued 350,000 shares of $0.001 par value restricted common stock for services valued at $136,500 or $0.39 per share. | |
| In March 2013 the Company issued 4,422,969 shares of $0.001 par value restricted common stock for services valued at $444,896 or $0.24 per share. | |
| In May 2013 the Company issued 250,000 shares of $0.001 par value restricted common stock for services valued at $60,000 or $0.24 per share. | |
| In August 2013 the Company issued 400,000 shares of $0.001 par value restricted common stock for services valued at $80,000 or $0.20 per share. | |
| In October 2013 the Company issued 60,000 shares of $0.001 par value restricted common stock for services valued at $15,000 or $0.25 per share. | |
| In November 2013 the Company issued 500,000 shares of $0.001 par value restricted common stock for cash of $95,000 or $0.19 per share that was used to pay expenses. | |
| In November 2013 the Company issued 425,000 shares of $0.001 par value restricted common stock for cash of $85,000 or $0.20 per share that was used to pay expenses. | |
| In November 2013 the Company issued 600,000 shares of $0.001 par value restricted common stock for R&D services valued at $114,000 or $0.20 per share. | |
| In December 2013 the Company issued 75,000 shares of $0.001 par value restricted common stock for services valued at $15,000 or $0.20 per share. | |
| In December 2013 the Company issued 1,800,000 shares of $0.001 par value restricted common stock for services valued at $306,000 or $0.17 per share. | |
| The Company has declared no dividends through December 31, 2013. |
| 4. Income Taxes | 12 Months Ended |
| Dec. 31, 2013 | |
| Income Tax Disclosure [Abstract] | ' |
| 4. Income Taxes | ' |
| Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740. At December 31, 2013 and December 31, 2012, the Company had approximately $5,494,149 and $3,002,666, respectively, in unused federal net operating loss carryforwards, which begin to expire principally in the year 2029. A deferred tax asset at each date of approximately $1,098,830 and $600,533 resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2013 and December 31, 2012 was approximately $498,297 and $141,590. | |
| The Company’s income tax filings are subject to audit by various taxing authorities. The Company’s open audit periods are 2010, 2011, and 2012, although, the statute of limitations for the 2010 tax year will expire effective March 15, 2014. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances. |
| 5. Related Party Transactions | 12 Months Ended |
| Dec. 31, 2013 | |
| Related Party Transactions [Abstract] | ' |
| 5. Related Party Transactions | ' |
| The Company has licensed its technology on an exclusive basis from Advanomics Corporation, a privately held Canadian company. Dr. Steve N. Slilaty, the Company’s Chief Executive Officer and a Director, is an Officer, Director and principal shareholder of Advanomics. In 2009 the Company issued an aggregate of 17,109,194 shares of its Common Stock valued at $73,000 and 850,000 shares of Series “A” Convertible Preferred Stock valued at $73,000 in exchange for this license, and has an option to purchase 2,000,000 shares of Advanomics common stock at $5 (US) per share within 1 year of September 30, 2009 as well as a second option to purchase an additional 1,000,000 shares of Licensor’s Common Stock at an exercise price of $10.00 (US) per share also for a 1 year term. The Company advanced further funds pursuant to this contract of $300,000. The total transaction costs to date of $446,000 have been written off as impaired. | |
| In September 2009, the Company acquired certain assets from Sunshine Bio Investments Inc. Michele Di Turi, the Company’s Chief Operating Officer and Director, is President and Director of Sunshine Bio Investments Inc. The Company issued 1,710,748 shares of Common Stock valued at $500,000 in consideration for these assets. Goodwill was recognized on the transaction of $499,976 which has been written off. |
| 6. Reverse Acquisition | 12 Months Ended |
| Dec. 31, 2013 | |
| Business Combinations [Abstract] | ' |
| 6. Reverse Acquisition | ' |
| On October 15, 2009 MWBS entered into an acquisition agreement (the "Agreement") with Sunshine Etopo, Inc., acquiring 100% of the outstanding common stock of Sunshine Etopo, Inc. through the issuance of 21,962,000 shares of its common stock with no readily available market price. The transaction was accounted for as a reverse acquisition as the shareholders of Sunshine Etopo, Inc. retained the majority of the outstanding common stock of MWBS after the share exchange. Effective with the Agreement, the Company's stockholders' equity was retroactively recapitalized as that of Sunshine Etopo, Inc., while 100% of the assets and liabilities of MWBS valued at $(29,465), consisting of notes payable and accrued interest of $29,465, were recorded as being acquired in the reverse acquisition for its 888,000 outstanding common shares on the acquisition date. (Immediately prior to the acquisition MWBS had 9,388,000 outstanding common shares. 8,500,000 of these shares were surrendered by the holders for cancellation). Subsequent to the October 15, 2009 recapitalization, MWBS and Sunshine Etopo, Inc. remain separate legal entities (with MWBS as the parent of Sunshine Etopo, Inc.). The accompanying consolidated financial statements exclude the financial position, results of operations and cash flows of MWBS prior to the October 15, 2009 acquisition. MWBS concurrent with the transaction changed its name to Sunshine Biopharma, Inc. | |
| 4. Income Taxes (Details Narrative) (USD $) | 12 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | |
| Income Taxes Details Narrative | ' | ' |
| Net operating loss carryforward | $5,494,149 | $3,002,666 |
| Carryforwards principally begin to expire | 1-Jan-29 | ' |
| Deferred tax asset | 1,098,830 | 600,533 |
| Less: Valuation Allowance | 1,098,830 | 600,533 |
| Change in valuation allowance | $498,297 | $141,590 |
